Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma

Area of Science:

• Hematology
• Oncology
• Biostatistics

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with variable prognoses.
• Existing prognostic systems, such as the International Prognostic Index (IPI), have limitations in accurately predicting outcomes for all DLBCL patients.

Purpose of the Study:

• To develop and validate a novel prognostic nomogram for diffuse large B-cell lymphoma (DLBCL).
• To compare the performance of the developed nomogram against established prognostic indices (IPI, R-IPI, NCCN-IPI).

Main Methods:

• A Cox proportional hazards model was used to develop the nomogram.
• Data from 1,070 consecutive DLBCL patients were analyzed, divided into primary (n=748) and validation (n=322) cohorts.
• Seven independent prognostic factors were identified: age, Ann Arbor stage, ECOG performance status, LDH, β2-microglobulin, CD5, and Ki-67 index.

Main Results:

• The developed nomogram demonstrated optimal agreement between predicted and observed survival.
• The nomogram achieved a concordance index (C-index) of 0.77 (primary) and 0.76 (validation), outperforming IPI, R-IPI, and NCCN-IPI (C-indices ranging from 0.69-0.74).
• Superior discrimination capability was observed for patients treated with rituximab plus CHOP (R-CHOP) or similar regimens.

Conclusions:

• The novel DLBCL-specific nomogram provides an accurate and reliable estimation of patient survival.
• The nomogram offers improved risk stratification compared to traditional prognostic systems, particularly for patients receiving R-CHOP-based chemotherapy.
• This tool can assist clinicians in optimizing individualized treatment strategies for DLBCL patients.